Webcast: Breakthrough Therapies for Acute Graft-Versus-Host-Disease
This CME-certified activity, Breakthrough Therapies for Acute Graft-Versus-Host-Disease, will provide focused instruction to healthcare professionals caring for patients with Graft-Versus-Host-Disease (GVHD). The activity is designed to provide clinically relevant updates on the treatment of patients with hematologic malignancies likely to undergo allogeneic stem cell transplantation. The activity will focus on increasing clinician knowledge and the ability to integrate changes into practice to improve patient outcomes. The program will highlight the changes in treatment that acute GVHD is experiencing due to recent implications of clinical trials and breakthrough designations of target agents. Topics for presentation will include: the antigens and microbiome characterstics involved in GVHD in addition to biomarkers for GVHD.
The Medical College of Wisconsin is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release June 27, 2017 to June 27, 2018.
This activity is supported by an unrestricted educational grant from Incyte.
This activity has been developed and is intended for transplant specialists, oncologists, hematologists and other healthcare professionals involved in the treatment of patients with GVHD.
Upon successful completion of this educational activity, participants should be better able to:
• Describe the overall clinical understanding of the pathophysiology, guidelines, and patient risk factors for GVHD
• Evaluate novel treatment options, especially breakthrough therapies, for GVHD
• Identify the importance of biomarkers for GVHD and the progress on finding more effective options
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in
the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
James Ferrara, MD, DSc discloses that he received royalties for a GVHD Biomarker patent and has intellectual property rights.
Motoko Koyama, MD, PhD has nothing to disclose.
Ernst Holler, MD, PhD discloses that he has been on the Advisory Board for Pharmacyclics. He also received honoraria from Prime Oncology and Sanofi.
The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose. Signed disclosures are on file at The Medical College of Wisconsin.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.